Gastroenterology · Medical Literature
Efficacy and Safety of a Tacrolimus Lipid Suspension Enema in Mild-to-Moderate Ulcerative Colitis: A Multicenter, Prospective, Double-Blind, Phase II Randomized Controlled Trial.
Abstract
A novel tacrolimus lipid suspension (TLS) enema was developed for the management of mild-to-moderate mesalamine-refractory ulcerative colitis (UC). The aim of this study was to evaluate the efficacy and safety of tacrolimus lipid suspension enema 2 mg (TLS-2) and 4 mg (TLS-4) in this patient population. In this multicenter, double-blind, Phase II trial, adult patients with mild-to-moderate mesalamine-refractory UC were randomized (1:1) to receive TLS-2 or TLS-4 for 4 weeks. Primary end points were change in the modified UC Disease Activity Index, remission rates, and time to resolution of rectal bleeding. Secondary end points included relapse rates, Short Inflammatory Bowel Disease Questionnaire scores up to 4 weeks after treatment, and clinical safety. A total of 60 patients were randomized to receive TLS-2 or TLS-4. Both groups exhibited significant reductions in the modified UC Disease Activity Index after 4 weeks (P 50% of patients. The median time to resolution of rectal bleeding was <14 days. Relapse occurred in 6% to 10% of patients within 4 weeks after treatment. Short Inflammatory Bowel Disease Questionnaire scores significantly improved in both arms, and no major safety issues were reported. Tacrolimus lipid suspension enema at both 2 and 4 mg doses was effective and well-tolerated. Both formulations also substantially improved patient-reported outcomes. CTRI/2015/10/006252.
Clinical relevance
In adult patients with mild-to-moderate mesalamine-refractory ulcerative colitis, do tacrolimus lipid suspension enemas at 2 mg (TLS-2) or 4 mg (TLS-4) administered for 4 weeks produce meaningful improvements in disease activity, remission rates, time to rectal bleeding resolution, relapse rates, and quality of life compared to each other? __SNAPSHOT__ {"studyDesign":"Multicenter, prospective, double-blind, Phase II randomized controlled trial (dose-comparison, two-arm parallel design; no placebo arm reported)","setting":"Multicenter; specific countries and institution types not reported in the abstract","sampleSize":"n=60 (TLS-2: 30, TLS-4: 30; exact per-arm allocation inferred from 1:1 randomization ratio stated in abstract — calculated)","population":"Adult patients with mild-to-moderate ulcerative colitis refractory to mesalamine therapy; additional inclusion/exclusion criteria not reported in the abstract","intervention":"Tacrolimus lipid suspension (TLS) enema 2 mg (TLS-2) administered rectally for 4 weeks; and tacrolimus lipid suspension enema 4 mg (TLS-4) administered rectally for 4 weeks","comparator":"Active dose-comparison only: TLS-2 vs. TLS-4; no placebo or standard-of-care control arm reported","primaryOutcome":"Three co-primary endpoints: (1) change from baseline in the modified UC Disease Activity Index (modified UCDAI); (2) clinical remission rate; (3) median time to resolution of rectal bleeding","followUp":"4 weeks of treatment; additional 4-week post-treatment observation period for relapse and SIBDQ assessment","fundingSource":"Not reported in the abstract; the trial formulation is associated with Intas Pharmaceuticals Limited, India (per registry records), suggesting potential industry involvement — funding not explicitly confirmed in the abstract"}
Key findings
Both TLS-2 and TLS-4 produced statistically significant reductions in the modified UCDAI after 4 weeks of treatment (P 50% of patients in each arm; exact remission rates per arm and between-group comparative statistics (e.g., relative risk, odds ratio, confidence intervals, p-value for between-group difference) are not reported in the abstract. The median time to resolution of rectal bleeding was less than 14 days in both groups; exact medians and any between-group comparison are not reported. Post-treatment relapse occurred in 6%–10% of patients within 4 weeks after completing therapy; per-arm breakdown is not reported. Short Inflammatory Bowel Disease Questionnaire (SIBDQ) scores improved significantly in both groups (statistical parameters not reported in the abstract). Specific adverse event rates, their severity, nature, or between-group differences in safety outcomes are not reported in the available abstract. No NNT or NNH can be calculated from the data provided, as absolute event rates per arm and a comparator arm are not reported.
Practice implications
This Phase II trial provides preliminary signal that rectally administered tacrolimus in a lipid suspension formulation — at both 2 mg and 4 mg doses — may induce clinical remission and accelerate rectal bleeding resolution in mesalamine-refractory mild-to-moderate UC within 4 weeks, with a low short-term post-treatment relapse rate of 6%–10%. However, several critical interpretive limitations must be acknowledged. First, this is a dose-comparison trial without a placebo or active standard-of-care control arm (e.g., corticosteroid enema), so no causal inference regarding efficacy above baseline or versus existing therapies can be drawn. The observed improvements could partly reflect spontaneous disease fluctuation, regression to the mean, or placebo effects. Second, the sample size (n=60) is small and underpowered to detect differences between dose groups or to characterize safety with meaningful precision. Third, between-group comparative statistics for the primary endpoints are not reported in the abstract, making it impossible to determine whether TLS-2 and TLS-4 differ meaningfully in efficacy or safety. Fourth, the co-primary endpoint structure raises multiplicity concerns that are not addressed in the abstract. Fifth, patient characteristics (e.g., disease extent, prior biologics, endoscopic severity) are incompletely described, limiting generalizability. Sixth, only an abstract is available for review, precluding assessment of randomization quality, allocation concealment, blinding integrity, outcome adjudication methods, and handling of missing data. This trial does not establish practice change; results should be interpreted as hypothesis-generating and as justification for a larger, placebo-controlled Phase III trial with a standardized comparator. __LIMITATIONS__ No placebo or active comparator arm (e.g., corticosteroid enema): limits causal efficacy attribution and direct positioning within current treatment algorithms.,Small sample size (n=60 total): markedly underpowered to detect between-dose differences, adequately characterize the adverse event profile, or assess subgroup effects.,Multiple co-primary endpoints without reported multiplicity correction increase the risk of type I error.,Between-group comparative statistics for primary endpoints not reported in the abstract, precluding assessment of dose-response or TLS-2 vs. TLS-4 superiority/non-inferiority.,Short follow-up duration (4 weeks treatment + 4 weeks post-treatment): insufficient to assess long-term remission maintenance, mucosal healing, or delayed adverse events including tacrolimus-related nephrotoxicity or opportunistic infections.,Phase II design: not powered or intended to establish definitive efficacy or safety; findings are preliminary by definition.,Absence of endoscopic remission as a primary or co-primary endpoint is a notable limitation by contemporary UC trial standards (e.g., FDA guidance on UC drug development).,Funding source not explicitly reported in the abstract; industry involvement is suggested by registry records, introducing potential sponsorship bias risk.,Generalizability is uncertain: patient demographics, geographic setting, disease extent (proctitis vs. left-sided vs. more extensive), and prior therapy exposure are not described in the abstract.,Abstract only available for review: randomization methodology, allocation concealment, blinding procedures, ITT vs. per-protocol analysis, and imputation methods cannot be assessed. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This small Phase II RCT (n=60) suggests that tacrolimus lipid suspension enemas at both 2 mg and 4 mg doses produce statistically significant reductions in disease activity and clinical remission in >50% of mesalamine-refractory mild-to-moderate UC patients within 4 weeks, with low short-term relapse rates. However, the absence of a placebo or active comparator arm, small sample size, short follow-up, and abstract-only availability preclude firm efficacy or safety conclusions. A well-powered, placebo-controlled or active-comparator Phase III RCT with endoscopic endpoints is required before this formulation can be considered for clinical adoption.